Spyre Therapeutics (SYRE) Receivables - Other (2016 - 2023)
Spyre Therapeutics (SYRE) has disclosed Receivables - Other for 7 consecutive years, with $163000.0 as the latest value for Q3 2023.
- For the quarter ending Q3 2023, Receivables - Other changed N/A year-over-year to $163000.0, compared with a TTM value of $163000.0 through Sep 2023, changed N/A, and an annual FY2022 reading of $375000.0, down 53.99% over the prior year.
- Receivables - Other was $163000.0 for Q3 2023 at Spyre Therapeutics, down from $330000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $1.0 million in Q1 2022 and bottomed at $163000.0 in Q3 2023.
- Average Receivables - Other over 3 years is $580000.0, with a median of $572500.0 recorded in 2021.
- Peak annual rise in Receivables - Other hit 67.39% in 2023, while the deepest fall reached 67.39% in 2023.
- Year by year, Receivables - Other stood at $815000.0 in 2021, then rose by 24.17% to $1.0 million in 2022, then plummeted by 83.89% to $163000.0 in 2023.
- Business Quant data shows Receivables - Other for SYRE at $163000.0 in Q3 2023, $330000.0 in Q1 2023, and $1.0 million in Q1 2022.